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Abstract
Pigment epithelium-derived factor (PEDF) is a broad-spectrum angiogenesis inhibitor that
displays potent anti-metastatic activity in multiple tumor types. We have previously shown that
PEDF prevents primary tumor growth and metastatic spread of human melanoma in mouse
experimental models. Consistent with these observations, PEDF expression is lost at the late
stages of melanoma progression, allowing melanoma cells to become angiogenic, migratory and
invasive. PEDF’s ability to modify the interplay between the host and tumor tissues strongly
supports its use as a therapeutic agent for the treatment of metastatic melanoma. However,
transition to the clinic requires a more detailed knowledge of the molecular mechanisms
underpinning PEDF’s activity. In this study we describe changes in the gene expression profile of
A375 human melanoma cells induced by PEDF over-expression. PEDF modulated diverse
categories of genes known to be involved in angiogenesis and migration. It downregulated
cytokines like interleukin 8 and extracellular matrix proteins like collagen IV, while it upregulated
fibronectin. Multiple transcripts previously described as contributing to the acquisition of
malignant phenotype by melanoma were also diminished by PEDF over-expression, among which
we validated galectin 3 and jagged 1. Additionally, PEDF downregulated S100β and melanoma
inhibitory activity (MIA), which are widely used in the pathological diagnosis of melanoma.
Interestingly, PEDF increased the expression of melanophilin and decreased rab27A, which are
relevant targets for melanosome transport; suggesting that PEDF could directly impinge on
melanocytic lineage-specific processes. Our study identifies new molecular targets and signaling
pathways that may potentially contribute to determine PEDF’s ability to restrict the aggressiveness
of A375 human melanoma cells.
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Introduction
Angiogenesis, the formation of new blood vessels from pre-existing ones [1], is an essential
process for tumor growth maintenance, dissemination and metastasis growth [2].
Angiogenesis is regulated by the dynamic balance between two general types of regulators,
inducers (pro-angiogenic) and inhibitors (anti-angiogenic). In normal tissues, vascular
quiescence is maintained due to a predominance of inhibitors, whose blocking action is
dominant over a wide array of inducers [3,4]. However, during tumor progression, the
angiogenic balance is inverted by genetic alterations as well as epigenetic regulation which
determine a predominance of inducers over inhibitors [5]. Strict dependency of tumor
growth and dissemination on sustained angiogenesis prompted the design of new therapeutic
strategies for cancer treatment based on angiogenesis blockade, either by using neutralizing
antibodies to relevant angiogenic factors or to their signaling receptors. Despite major
impact of these strategies in preclinical models [6], both preclinical and clinical studies
show that when a single angiogenic factor is targeted, the tumors acquire resistance to
therapy, most likely due to production of alternative angiogenesis inducers [7]. In order to
overcome these limitations a number of alternative approaches are currently being tested [8–
11]. One such strategy involves restoration of endogenous angiogenesis inhibitors, whose
expression is lost during malignant progression and which block the action of multiple
inducers [11]. Treatment of xenografted tumors with endogenous anti-angiogenic factors
efficiently halts primary tumor growth and significantly impairs metastasis [12–14].
However, translating endogenous inhibitors of angiogenesis into the clinic requires deeper
knowledge of their biological effects and underlying molecular mediators.
Pigment epithelium-derived factor (PEDF) is a 50 kDa secreted glycoprotein and a non-
functional member of the serine protease inhibitor (Serpin) superfamily [15,16]. PEDF plays
a critical role in maintaining vascular quiescence and controls the angiogenic switch in
multiple tissues [17,18]. Potent anti-tumor and anti-metastatic effects of PEDF were
demonstrated in mouse experimental models using a variety of cancer cell lines, and an
inverse correlation between PEDF levels and aggressiveness was also shown for different
types of cancers [19]. We have previously described PEDF’s anti-tumor and anti-metastatic
effects in melanoma [19,20], a type of cancer that displays a relevant angiogenic activity
[21,22]. PEDF ability to inhibit melanoma growth and metastasis is based on its dual action
on endothelial and tumor cells. In both cell types, PEDF can cause apoptosis and impair
migratory and invasive capacity. Recent reports have identified non-overlapping epitopes on
PEDF molecule responsible for its diverse biological actions [23–25]. We have also found
that PEDF is expressed at high levels in normal skin melanocytes, and that the loss of PEDF
expression enables the switch of melanoma cells from proliferative to invasive phenotype
highlighting the relevance of this factor in the control of melanoma progression [26]. Thus
we propose that restoration of PEDF expression by delivery of recombinant PEDF or short
PEDF-derived peptides could be employed as a therapeutic strategy in advanced melanoma,
which is a especially aggressive cancer refractory to currently available drugs [27]. Using
this multifaceted factor, which targets diverse biological processes critical for cancer
progression, may serve double purpose by obliterating the vasculature and switching off
their ability to invade, leading to reduced metastatic spread of melanoma cells [19]. Despite
the interesting biological properties described for PEDF, a detailed understanding of its
molecular mechanisms remains elusive.
In this study we identify novel candidate factors and pathways that could mediate the effects
of PEDF on A375 human melanoma cells. Using global gene expression profiling analysis,
we have found that PEDF over-expression in A375 cells mostly downregulated distinct sets
of genes, which fall into several functional categories including the control of angiogenesis
and several other functions required for melanoma progression; while it increased
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expression of some relevant transcripts such as fibronectin and melanophilin. Identified
targets provide molecular insight into PEDF’s actions leading to reduced aggressiveness of
A375 melanoma cells.
Methods
Cell culture
A375 human melanoma cell line, originally established in culture from a lymph node
metastasis of a melanoma patient [28,29], was kindly provided by Dr Vidal-Vanaclocha
(Universidad del Pais Vasco, Bilbao, Spain). UCD-Mel-N human melanoma cell line was
originally derived from a patient with multiple primary melanoma tumors, and generously
provided by Dr. E. Medrano [30]. C8161 human melanoma cell line was initially isolated
from an abdominal wall metastasis of a cutaneous melanoma patient, and generously
provided by Dr. M. Hendrix [31]. All melanoma cell lines were grown in DMEM (Gibco,
New York, NY, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco), 2 mM
glutamine (Gibco), 50 μg/ml streptomycin (Gibco), 50 U/ml penicillin (Gibco) and 2.5 μg/
ml fungizone (Sigma, St Louis, MO, USA).
Generation of PEDF over-expressing cell lines
A375 melanoma cells were seeded into 21 cm2 plates and 24 h later they were transfected
with 10.8 μg pCEP4-PEDF plasmid (provided by Dr Bouck, Northwestern University,
Chicago, IL, USA) or control pCEP4 plasmid and 21.6 μl jetPEI (Polyplus Transfection,
Illkirch, France) for 4 h. Pooled transfected cells (herein after referred to as A375-pCEP4-
PEDF Pool and A375-pCEP4 Pool) were selected using 300 μg/ml hygromycin B (Sigma)
for 2 weeks and used for the gene expression profile study. In an independent transfection a
number of isolated clones were selected as described above and used for the validation of
target genes identified using the pools.
Further validation of selected target genes was carried out by transient over-expression using
lentivirus. The lentiviral construct encoding the full-length human PEDF cDNA in the
prrl.CMV.EGFP.wpre.SIN lentiviral vector (kindly provided by A Bernad, Centro Nacional
de Investigaciones Cardiovasculares, Madrid, Spain) has been previously reported [26].
Lentiviral particles were produced as described earlier [28]. Transduction of A375
melanoma cells was performed by incubating cells with lentiviruses at a multiplicity of
infection (MOI) of 10 in the presence of 8 μg/ml polybrene (Sigma) for 8 h, typically
yielding more than 95% transduced (GFP-positive) cells. After 72 h, PEDF over-expression
was assessed in transient studies. PEDF-over-expressing UCD-Mel-N and C8161 melanoma
cell lines (UCD-PEDF, C8161-PEDF) and their respective controls (UCD-GFP, C8161-
GFP) have been described previously [20,26].
Western blot
Conditioned media (CM) were prepared and analyzed as described earlier [32], and 1.5 μg
CM were loaded per lane. PEDF monoclonal antibody (Chemicon, Temecula, CA, USA)
was diluted 1:1200.
IL8 ELISA
Secreted IL8 protein levels in 48 h CM were quantified using Human CXCL8/IL8
Quantikine ELISA Kit (R&D) following manufacturer’s instructions.
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Reporter assays
We used pGL3-basic reporter plasmids (Promega, Madison, WI, USA) containing the
Firefly luciferase gene (Luc) under the control of the −2000 bp fragment of the human IL8
gene promoter (pGL-2000-IL8-Luc, provided by Dr Raingeaud, INSERM, Chatenay-
Malabry, France) [33]; and the pRL-SV40 plasmid (Promega, Madison, WI, USA)
containing the Renilla reniformes luciferase gene (Renilla) under the control of the SV40
virus promoter as a control to correct for the efficiency of transfection. 5×104 cells were
seeded onto 2 cm2 wells 24 h before transfection, each condition in triplicate. Then, cells
were incubated with 1 μl Lipofectamine 2000 (Sigma), 300 ng pGL-2000-IL8-Luc and 20
ng pRL-SV40 plasmids in 50 μl OptiMEM (Gibco) per well for 4 h, and medium was
changed. Next day, cells were incubated with 10% FBS or 10 ng/ml tumor necrosis alpha
(TNFα) in serum-free medium for 24 h, and then plates were frozen at −80°C. Analysis of
Luc and Renilla activity was performed using the Dual Luciferase Reporter Assay System
(Promega) and a Lumat LB9507 luminometer (Berthold Technologies, Bad Wildbad,
Germany). The Luc activity was then normalized to Renilla activity.
RNA extraction and quantitative RT-PCR
Total RNA was extracted using TRIzol (Molecular Research Center Inc., Cincinnati, OH,
USA) and was retro-transcribed to cDNA using High-Capacity cDNA Archive Kit (Applied
Biosystems, Foster City, CA, USA). See Supplementary Methods and Supplementary Table
1 for TaqMan (Applied Biosystems) and Universal Probe Library (UPL) (Roche, Basel,
Switzerland) probes and oligonucleotides used. The quantitative PCR reaction was
performed in an ABI Prism 7900 HT thermal cycler (Applied Biosystems). Thermal cycling
conditions consisted of a denaturing step at 95°C for 10 min, 40 cycles of denaturing at
95°C for 15 s and annealing and elongation at 60°C for 60 s. Each condition was assessed in
triplicate. Relative mRNA levels were determined using the comparative CT method.
Microarray hybridization and data analysis
Global gene expression profiles of A375-pCEP4 Pool and A375-pCEP4-PEDF Pool cells
were determined using whole genome oligonucleotide GeneChip Human Genome-133 plus
2.0 microarrays (Affymetrix, Santa Clara, CA). Microarrays were hybridized in duplicate
with RNAs from two independent experiments. RNA integrity was determined using a
Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). Biotinylated cRNA was
synthesized from total RNA using the 3′ Amplification One-cycle Target labeling kit
(Affymetrix). Briefly, 2 μg of RNA were reverse transcribed to produce first strand cDNA
using an oligodeoxythymidylic acid 24 primer with a T7 RNA polymerase promoter site
added to the 5′ end. After second strand synthesis, in vitro transcription was performed using
T7 RNA polymerase and biotinylated nucleotides, to produce biotin-labeled cRNA. Ten μg
cRNA was fragmented at 95° C for 35 min into 35–200 bases in length. Fragmented cRNAs
were hybridized to microarrays at 45°C for 16 h in an oven at 60 rpm.
Each microarray was washed and stained in the Affymetrix Fluidics Station 450 following
the standard protocols developed by Affymetrix. Microarrays were scanned in an
Affymetrix GeneChip® Scanner 3000 7G. Normalized gene expression values were
obtained using GCRMA algorithm [34]. To determine statistically significant changes in
each individual comparison, we used Microarray Suite (MAS 5.0) comparison analysis from
Affymetrix (Statistical Algorithm Reference Guide). In this analysis a change algorithm
generates a Change p-value and an associated Change (Increase, Decrease or NoChange).
Probe sets were considered as regulated when there was a significant Change (Increase or
Decrease) and at least a two-fold upregulation or downregulation in A375-pCEP4-PEDF
compared to A375-pCEP4 cells in both independent hybridizations (regulated probe sets are
listed in Supplementary Table 2). Heat maps of regulated genes were generated using
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Multiexperimental Viewer software (Microarray Software Suite, http://www.tm4.org). Most
regulated genes were classified according to their function into biological process categories
from the Gene Ontology database (http://www.geneontology.org/). This classification was
further completed with new “melanoma progression-related” categories according to
information from Gene database (NCBI) and published studies in PubMed.
Invasion assay
Cell invasion was evaluated using cell Invasion Assay Kit (Chemicon) following the
manufacturer’s instructions. In brief, cells were serum-starved 16 h prior to seeding, and
10% FBS was used as chemoattractant. After 24 h, non-invaded cells were wiped off using a
cotton swab, and the filters were stained with Diff Quik (Dade Behring, Newark, DE, USA).
Invaded cells were counted at ten areas of maximum invasion under a light microscope at
40× magnification. Average ± standard deviation (SD) values shown are representative of at
least three independent experiments.
Statistical analysis
All statistical analyses were performed using GraphPad Instat (GraphPad Software, San
Diego, CA, USA). P values ≤ 0.05 were considered as significant.
Results
Functional grouping of genes modulated by PEDF in A375 human melanoma cells
To gain insight into the molecular mechanisms underlying effects of PEDF on melanoma,
we performed genome-wide analysis of the changes in gene expression induced by PEDF
over-expression in A375 human melanoma cell line. A375 cells expressed very low
endogenous levels of PEDF compared to other human melanoma cell lines tested [26], and
PEDF over-expression significantly reduced its metastatic potential in mouse models [20].
We generated a pool of A375 melanoma cells stably expressing high levels of PEDF (A375-
pCEP4-PEDF Pool) and a pool of empty vector-transfected A375 cells (A375-pCEP4 Pool).
PEDF expression was assessed by Western blot of conditioned medium (CM) (Fig. 1a) and
quantitative RT-PCR (Fig. 1b). PEDF over-expression reduced the invasive ability of A375
cells (Fig. 1c), in agreement with previously described results in other human melanoma cell
lines [20,26,35].
We hybridized RNAs isolated from A375-pCEP4-PEDF Pool and A375-pCEP4 Pool cells
to oligonucleotide Affymetrix microarrays. The results from two independent experiments
were analyzed. Considering a two-fold cut-off, 757 probe sets showed differential
expression (Supplementary Table 2). Among these, 470 corresponded to characterized genes
annotated in the National Center for Biotechnology Information (NCBI). The majority of
genes were downregulated by PEDF over-expression (340 genes); while 140 genes were
upregulated (heat map is shown in Fig. 2a). The differentially regulated genes were
classified according to their function into biological process categories from the Gene
Ontology database. We expanded this analysis to include additional categories specifically
related to melanoma biology, which are not included at Gene Ontology database, using
literature searches for the data supporting the functional role of genes regulated by PEDF
(Fig. 2b and Table 1). Significant number of genes (highlighted in the lower boxes in Fig.
2b) involved in angiogenesis, adhesion, migration, invasion and matrix degradation were
regulated by PEDF. The trend of the regulation was in agreement with its previously
described inhibitory effects on melanoma [20]. Interestingly, several genes shown in other
studies as relevant for melanoma progression or lineage-specific functions were also
modulated by PEDF.
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Genes involved in the control of angiogenesis and invasion modulated by PEDF in A375
human melanoma cells
Genes that determine the angiogenic phenotype and the migratory and invasive ability of
melanoma cells were modulated by PEDF over-expression in A375 cells (Fig. 2b and Table
1). A number of soluble factors with pro-angiogenic or chemotactic properties were
downregulated upon PEDF over-expression, including interleukin 8 (IL8), transforming
growth factor alpha (TGFA) and transforming growth factor beta-induced (TGFBI) [3]. The
downregulation was confirmed by quantitative RT-PCR for IL8 and TGFA (Fig. 3a) and by
ELISA for IL8 (Fig. 3b).
IL8 augments the angiogenic potential of melanoma cells and activates their proliferation
and migration [36], and its levels directly correlate with melanoma metastatic potential [37].
Considering IL8 key role in melanoma progression [36], we sought to further analyze its
regulation by PEDF. We confirmed IL8 downregulation in PEDF-over-expressing A375
clones and UCD-Mel-N and C8161 melanoma cell lines (Fig. 4). We also analyzed the
effect of transient PEDF over-expression on IL8 levels. A375 cells were efficiently
transduced (>95% infected cells) with a lentivirus encoding PEDF (A375-lenti-PEDF) or
control lentivirus (A375-lenti-GFP) (Fig. 5a). PEDF expression was measured 72 h after
transduction by Western blot of CM (Fig. 5b) and quantitative RT-PCR (Fig. 5c). IL8
mRNA (Fig. 5d) and protein (Fig. 5e) levels were significantly decreased by transient PEDF
over-expression. Low levels of IL8 expression were maintained at least for two weeks after
lentiviral transduction (data not shown). We also assessed if the decreased IL8 expression
levels by PEDF was mediated by transcriptional regulation. We analyzed IL8 promoter
activity using a reporter construct encompassing 2000 bp upstream of the IL8 transcription
start site. In melanoma cells transiently or stably over-expressing PEDF and cultured in 10%
serum or treated with TNFα to stimulate IL8 production [33], we found no change in the IL8
promoter activity (Fig. 5f and data not shown).
Proteases or protease inhibitors from diverse families were predominantly downregulated by
PEDF over-expression in A375 cells. This group included TIMPs (tissue inhibitors of
metalloproteinases), ADAMs (a disintegrin and metalloproteinase domain), ADAMTSs (a
disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif) or
SERPINs (serine (or cysteine) proteinase inhibitor) (Fig. 2b and Table 1). Moreover, PEDF
modified the expression of extracellular matrix proteins involved in migration as well as
angiogenesis, such as collagen IV (COL4A2) [38] or fibronectin (FN1) [39], whose
regulation was validated by quantitative RT-PCR (Fig. 3a). Even though the downregulation
of COL4A2 by PEDF was less than two-fold in the microarray, a more pronounced decrease
was found by quantitative RT-PCR. Other factors involved in adhesion and migration,
including integrins, cadherins and protocadherins, were also downregulated in the presence
of PEDF (Fig. 2b and Table 1). Furthermore, several molecules of the VEGF pathway,
which could potentially contribute to control of melanoma proliferation and/or migration
[22], such as fms-related tyrosine kinase 1 (FLT1) and neuropilin 2 (NRP2) (Fig. 2b and
Table 1), were reduced by PEDF.
Genes implicated in melanoma progression modulated by PEDF in A375 human melanoma
cells
Multiple genes previously involved in melanoma progression [40–42] were modulated by
PEDF over-expression in A375 cells with the trend consistent with decreased aggressiveness
(Fig. 2b and Table 1). This group included genes of the Notch pathway [43], such as notch
homolog 2 (NOTCH2NL) and jagged 1 (JAG1); and of the Wnt pathway [44], including
Dickkopf 1 and 3 (DKK1 and DKK3), frizzled 1 and 2 (FZD1, FZD2) and lymphoid
enhancer-binding factor 1 (LEF1). The decreased expression of JAG1 in the presence of
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PEDF was confirmed by quantitative RT-PCR in transfection pools (Fig. 3a) and two
independent clones (Fig. 4). Likewise, PEDF downregulated other genes previously
described to participate in melanoma progression by enhancing proliferation or invasion,
such as fibroblast growth factor 13 (FGF13) [41], insulin-like growth factor binding protein
3 (IGFBP3) [45], inhibin, beta A (INHBA) [42] and galectin 3 (LGALS3) [46]. We validated
the regulation of FGF13, IGFBP3 and LGALS3 by quantitative RT-PCR (Figs. 3a and 4).
PEDF also altered the expression of transcription factors potentially relevant for melanocyte
transformation and/or melanoma progression including T-box 2 (TBX2) [47], SOX2 and
SOX5 [48], which were downregulated; and SOX9 and SOX11 [49], whose expression was
increased. This regulation trend was consistent with reduced tumorigenicity and delayed
progression. Moreover, nuclear factor of activated T-cells (NFATC2), involved in mediating
PEDF’s intracellular signaling [50], also had its expression decreased by PEDF (Fig. 2b and
Table 1).
Interestingly, a number of melanoma markers whose expression increases in the course of
malignant progression were predominantly downregulated in PEDF over-expressing A375
cells, such as melanoma inhibitory activity (MIA) and several S100 calcium binding protein
family members (Fig. 2b and Table 1); the decreased MIA and S100B expression was
confirmed by quantitative RT-PCR (Figs. 3a and 4).
Finally, PEDF also diminished the expression of factors involved in the inhibition of
apoptosis, such as Bcl2-related protein A1 (BCL2A1); or in cell proliferation, like insulin-
like growth factor 1 receptor (IGF1R) and IGFBP 2, 5 and 7, among others; as well as a
number of cytokines and genes involved in metabolism (Fig. 2b and Table 1).
Genes specific for melanocyte lineage functions modulated by PEDF in A375 human
melanoma cells
Genes involved in melanocytic lineage-specific functions, such as melanogenesis, were
modulated by PEDF over-expression in A375 cells [51]. Melanosomes are specialized
membrane vesicles where melanin is synthesized, stored and eventually delivered to the cell
membrane, to be transferred to adjacent keratinocytes [52]. Two regulators of melanosome
trafficking, the small GTP-binding protein RAB27A and its effector melanophilin (MLPH)
[53], were regulated by PEDF over-expression (Fig. 2b and Table 1) and this regulation was
confirmed by quantitative RT-PCR in transfection pools (Fig. 3a) and two independent
clones (Fig. 4).
Discussion
PEDF is an emerging agent for the targeted anti-cancer therapies. The combination of the
potent and diverse effects on tumor cells, as well as its anti-angiogenic action; make it
especially compelling, particularly for advanced melanoma, a highly aggressive cancer
which responds poorly to the currently available treatments. Despite the growing interest in
the therapeutic applications of PEDF, very few studies used global expression analysis to
seek molecular mediators underlying its multiple biological actions [54–56]. In this study we
describe genome-wide changes in the expression profile of A375 aggressive human
melanoma cells caused by PEDF.
In general, PEDF decreased the expression of numerous genes involved in key tumor-
specific functions critical for melanoma progression and whose products are likely to
contribute to PEDF known anti-cancer properties.
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Firstly, several factors that contribute to angiogenesis and chemotaxis were diminished due
to PEDF expression. This is consistent with previous observations by us and others
describing PEDF-dependent inhibition of angiogenic potential and motility of the melanoma
cells [20,35,57]. Decreased expression of these genes weakened the ability of melanoma
cells to induce neovascularization. The decrease of VEGF mRNA in PEDF-expressing cells
was less than two-fold; hence, it was not included in our master list. However, VEGF
protein levels were decreased to a larger extent than mRNA [20,58,59], suggesting
additional post-transcriptional events. A recent expression profiling study in prostate
adenocarcinoma has also shown downregulation of angiogenesis-related genes upon
treatment with recombinant PEDF, which included fibroblast growth factor 3, neuropilin 1,
brain-specific angiogenesis inhibitor 2 and endothelial PAS domain protein 1 [55]. In our
study, neuropilin and fibroblast growth factor family members were also regulated by PEDF
in A375 melanoma cells. IL8, whose expression is also diminished in the presence of PEDF,
falls in the same category. IL8 is a multifunctional cytokine, which stimulates angiogenesis,
proliferation and migration [36]. IL8 levels directly correlate with the metastatic potential
and aggressiveness of melanoma [37,60]. IL8 protein and mRNA were significantly
decreased due to the transient or stable PEDF over-expression in A375 melanoma cells.
However, IL8 regulation by PEDF in A375 melanoma cells seemed to be mainly post-
transcriptional as we were unable to register a decrease in the activity of IL8 reporter
constructs upon PEDF over-expression, despite the presence of multiple binding sites for the
transcription factors potentially regulated by PEDF in A375 melanoma cells and other cell
types, and involved in IL8 regulation, like NFATC2 [50,61]. The promoter region used in
our study has been previously shown to respond to a number of IL8 stimulating factors
including hypoxia [62], acidosis [63], TNFα and IL1 [64].
Altered expression of adhesion and extracellular matrix–related molecules by PEDF may, in
addition to the chemokine expression, also contribute to PEDF-dependent inhibition of
melanoma migration and invasion. In our study, PEDF decreased collagen IV (COL4A2)
expression, an essential component of the basement membrane, which is important for
angiogenesis, adhesion and migration [38,65]. PEDF also enhanced expression of
fibronectin, an extracellular matrix protein involved in adhesion, proliferation and migration
through its binding to integrins [39]. Increased fibronectin could enhance cell adhesion
which may impair invasiveness. A recent report shows that silencing of fibronectin in
thyroid carcinoma cells enhances tumor growth and metastasis [66].
PEDF over-expression in A375 cells modified the expression of a number of genes
attributed in other studies to the malignant progression of human melanoma, including
activin A, insulin-like growth factor binding protein 3 and galectin 3, several members of
the SOX transcription factor family, and the genes that belong to the Notch (NOTCH2NL,
JAG1) [43] or Wnt (DKK1, FZD1, LEF1) [44,67] pathways. Importantly, PEDF
downregulated several melanoma markers currently utilized in clinico-pathological
diagnosis of melanoma, such as S100β [68]; or used as prognostic factors for relapse and
metastasis, like S100β or MIA [69]. Collectively, these changes in the expression pattern of
the genes related to melanoma progression may reflect the switch to a less aggressive
phenotype by PEDF-expressing melanoma cells and supports the therapeutic potential of
PEDF in this type of cancer.
Interestingly, PEDF over-expression in A375 cells altered the expression of genes involved
in functions specific for melanocyte lineage, upregulating MLPH and downregulating
RAB27A. These genes are involved in melanosome trafficking and therefore play a key role
in melanin transfer [52]. PEDF has been detected in immature melanosomes of melanoma
cells [70], and prior reports have proposed its participation in pigment production through
induction of tyrosinase [71] and promotion of melanosome maturation in retinal pigment
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epithelium cells [72]. We have previously described that PEDF is expressed at high levels in
melanocytes, and restricts their proliferative and migratory potential [26]. Modulation of
MLPH and RAB27A expression by PEDF in A375 cells suggests that it could also mediate
melanocyte-specific processes, such melanin distribution in the skin. In keeping with this
new role, we found that PEDF increases the expression of SOX9, which was recently
implicated in control of melanocyte differentiation and pigmentation, acting upstream of
microphthalmia-associated transcription factor (MITF) [73].
In summary, our study points to novel molecular targets and signaling pathways that may
potentially contribute to determine PEDF’s ability to restrict the aggressiveness of A375 and
other human melanoma cells. We also stumbled upon unanticipated PEDF targets involved
in melanocytic lineage-specific functions. Our results presented set the stage for further in-
depth studies of the molecular mechanisms underlying PEDF effects in melanoma, which
would be essential for the clinical translation of this factor.
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Fig. 1.
Characterization of PEDF-over-expressing A375 cell lines. (a) Western blot analysis of
secreted extracellular PEDF (PEDFe) protein in 48 h conditioned medium (CM) from
control (A375-pCEP4 Pool) and PEDF-over-expressing (A375-pCEP4-PEDF Pool) cells.
Numbers below blot show densitometry values normalized to A375-pCEP4 Pool expression.
(b) Quantitative RT-PCR analysis of PEDF mRNA levels in A375-pCEP4 Pool and A375-
pCEP4-PEDF Pool cells. PEDF mRNA levels are shown relative to A375-pCEP4 Pool after
normalization to GAPDH. Bars represent average ± standard deviation (SD). (c) Invasion
assay of A375-pCEP4 Pool and A375-pCEP4-PEDF Pool cells toward 10% FBS for 24 h.
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Statistical significance was determined by Student’s t-test (****, p<0.0001). Results are
representative of two independent experiments.
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Fig. 2.
Distribution in functional categories of genes regulated by PEDF in A375 melanoma cells.
(a) Heat map of expression of genes regulated by PEDF in two independent hybridizations
(Hybr. 1 and Hybr. 2) of A375-pCEP4-PEDF Pool cells compared to control A375-pCEP4
Pool cells. Coloring represents normalized signal intensity of the ratio log2 (A375-pCEP4-
PEDF Pool/A375-pCEP4 Pool): red, upregulation; black, no change; green, downregulation.
(b) Diagram showing genes regulated by PEDF grouped into biological processes and/or
functional categories as described in the main text. Percentage of regulated genes in each
category relative to total number of regulated genes is shown. For some categories the most
relevant genes are listed in the lower boxes, being shown in red when upregulated and in
green when downregulated in A375-pCEP4-PEDF Pool compared to A375-pCEP4 Pool.
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Fig. 3.
Validation of candidate target genes regulated by PEDF in A375 melanoma cells. (a)
Quantitative RT-PCR analysis of mRNA levels of genes related to: 1) angiogenesis/
adhesion/migration/invasion: COL4A2, FN1, IL8 and TGFA; 2) melanoma progression:
FGF13, IGFBP3, JAG1 and LGALS3; 3) melanoma markers: MIA and S100B; 4) melanin
secretion: MLPH and RAB27A. Empty bars correspond to A375-pCEP4 Pool cells and filled
bars to A375-pCEP4-PEDF Pool cells. For each gene mRNA levels are shown relative to
A375-pCEP4 Pool after normalization to GAPDH. Bars represent average ± SD. Statistical
significance was determined by Student’s t-test or Welch-corrected t-test (the latter for
COL4A2, TGFA, LGALS3, MLPH and S100B) (*, p<0.05; **, p<0.01; ***, p<0.001; ****,
p<0.0001). (b) ELISA analysis of secreted IL8 protein levels in 48 h CM from A375-pCEP4
Pool and A375-pCEP4-PEDF Pool cells. Bars represent average ± SD. Statistical
significance was determined by Student’s t-test (****, p<0.0001). Results are representative
of two independent experiments.
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Fig. 4.
Confirmation of regulation of several target genes in other PEDF-over-expressing melanoma
cell lines. (a) Quantitative RT-PCR analysis of PEDF mRNA levels in A375-pCEP4 Pool,
A375-pCEP4-PEDF Clone 1 and A375-pCEP4-PEDF Clone 4 cells. PEDF mRNA levels
are shown relative to A375-pCEP4 Pool after GADPH normalization. Bars represent
average ± SD. (b) Quantitative RT-PCR analysis of IL8 (left panel), JAG1 (middle panel)
and MLPH (right panel) mRNA levels in A375-pCEP4 Pool, A375-pCEP4-PEDF Clone 1
and A375-pCEP4-PEDF Clone 4 cells. For each gene mRNA levels are shown relative to
A375-pCEP4 Pool after GAPDH normalization. Bars represent average ± SD. Statistical
significance was determined by one-way ANOVA test using Tukey-Kramer post-test (*,
p<0.05; ***, p<0.001). Results are representative of two independent experiments. (c)
Western blot analysis of PEDFe protein in 48 h CM from control (UCD-GFP or C8161-
GFP) and PEDF-over-expressing (UCD-PEDF or C8161-PEDF) cells. Numbers below blots
show densitometry values normalized to each control cells expression. (d) Quantitative RT-
PCR analysis of IGFBP3, MIA and IL8 mRNA levels in UCD-GFP, UCD-PEDF, C8161-
GFP and C8161-PEDF cells. For each gene mRNA levels are shown relative to control cells
after GAPDH normalization. Bars represent average ± SD. Statistical significance was
determined by Student’s t-test (***, p<0.001; ****, p<0.0001). Results are representative of
two independent experiments.
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Fig. 5.
Validation of regulation of IL8 by transient transduction of A375 melanoma cells using
lentivirus-PEDF. (a) Transduction efficiency of A375 melanoma cell line after infection
with control (A375-lenti-GFP) or PEDF (A375-lenti-PEDF) lentivirus. Fluorescence images
show more than 95% GFP-positive cells after 72 h of infection. Corresponding phase-
contrast images are shown. (b) Western blot analysis of secreted extracellular PEDF
(PEDFe) protein in 48 h CM from A375 melanoma cell line after 72 h of transduction with
control lentivirus-GFP (A375-lenti-GFP) or lentivirus-PEDF (A375-lenti-PEDF). Numbers
below blot show densitometry values relative to A375-lenti-GFP. (c) Quantitative RT-PCR
analysis of PEDF mRNA levels in A375 melanoma cell line after 72 h of transduction with
control lentivirus-GFP (A375-lenti-GFP) or lentivirus-PEDF (A375-lenti-PEDF). PEDF
mRNA levels are shown relative to A375-lenti-GFP after normalization to GAPDH. Bars
represent average ± SD. (d) Quantitative RT-PCR analysis of IL8 mRNA levels in A375
melanoma cell line after 72 h of transduction with control lentivirus-GFP (A375-lenti-GFP)
or lentivirus-PEDF (A375-lenti-PEDF). IL8 mRNA levels are shown relative to A375-lenti-
GFP after normalization to GAPDH. Bars represent average ± SD. Statistical significance
was determined by Student’s t-test (*, p<0.01). (e) ELISA analysis of secreted IL8 protein
levels in 48 h CM from A375 melanoma cell line after 72 h of transduction with control
lentivirus-GFP (A375-lenti-GFP) or lentivirus-PEDF (A375-lenti- PEDF). Bars represent
average ± SD. Statistical significance was determined by Student’s t-test (**, p<0.01). (f)
IL8 transcriptional activity reporter assay in the A375-lenti-GFP and A375-lenti-PEDF
melanoma cells mentioned above after 24 h treatment with 10% FBS or 10 ng/ml TNFα.
Luciferase levels relative to A375-lenti-GFP in 10% FBS after normalization to renilla
levels are shown. Bars represent average ± SD. Results are representative of two
independent experiments.
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Table 1
Distribution in functional categories of genes regulated by PEDF in A375 human
melanoma cell line
Selected relevant genes regulated by PEDFe are shown classified into functional categories described in the
main text. Upregulated genes are included at the top of the list followed by downregulated genes. Shown are
gene symbol, description and the linear ratio of GCRMA-normalized expression PEDF/control in the two
hybridizations from independently isolated RNAs from A375-pCEP4-PEDF Pool y A375-pCEP4 Pool cells
(Hybr. 1 and Hybr. 2).
ANGIOGENESIS/ADHESION/MIGRATION/INVASION
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
FN1 Fibronectin 1 14.22 16.52
VEGFC vascular endothelial growth factor C 3.13 4.64
FLT1 Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor
receptor)
0.05 0.07
IL8 Interleukin 8 0.36 0.36
ITGB3 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 0.30 0.26
ITGB8 Integrin, beta 8 0.11 0.19
NRP2 Neuropilin 2 0.40 0.41
PCDH10 Protocadherin 10 0.10 0.12
PCDH17 Protocadherin 17 0.34 0.27
PCDHA9 Protocadherin alpha 9 0.46 0.48
PCDHB7 Protocadherin beta 7 0.34 0.34
PELO Integrin, alpha 1 0.12 0.15
TGFA Transforming growth factor, alpha 0.03 0.04
TGFBI Transforming growth factor, beta-induced, 68kDa 0.41 0.43
PROTEASES
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
ADAMTS6 A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 6 3.39 8.66
ADAM10 A disintegrin and metalloproteinase domain 10 0.46 0.46
ADAM12 A disintegrin and metalloproteinase domain 12 (meltrin alpha) 0.27 0.47
ADAM19 A disintegrin and metalloproteinase domain 19 (meltrin beta) 0.06 0.09
ADAM23 A disintegrin and metalloproteinase domain 23 0.08 0.10
CTSH Cathepsin H 0.17 0.30
CTSK Cathepsin K (pycnodysostosis) 0.08 0.10
PLAT Plasminogen activator, tissue 0.39 0.40
PRSS11 protease, serine, 11 (IGF binding) 0.07 0.04
SERPINA3 Serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3 0.05 0.04
SERPIND1 Serine (or cysteine) proteinase inhibitor, clade D (heparin cofactor), member 1 0.07 0.07
TIMP1 Tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor) 0.33 0.32
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MELANIN SECRETION
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
MLPH Melanophilin 15.70 28.90
RAB27A RAB27A, member RAS oncogene family 0.31 0.22
MELANOMA PROGRESSION
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
DKK1 Dickkopf homolog 1 (Xenopus laevis) 2.86 2.87
DKK3 Dickkopf homolog 3 (Xenopus laevis) 2.28 2.85
FZD2 Frizzled homolog 2 (Drosophila) 2.60 2.38
FGF13 Fibroblast growth factor 13 0.14 0.08
FZD1 Frizzled homolog 1 (Drosophila) 0.37 0.42
GAGE1 G antigen 1 0.35 0.46
GAGE2 G antigen 2 0.11 0.10
GAGE4 G antigen 4 0.45 0.38
GAGE5 G antigen 5 0.24 0.31
IGFBP3 Insulin-like growth factor binding protein 3 0.11 0.22
INHBA Inhibin, beta A (activin A, activin AB alpha polypeptide) 0.18 0.24
JAG1 Jagged 1 (Alagille syndrome) 0.14 0.13
LEF1 Lymphoid enhancer-binding factor 1 0.48 0.37
LGALS3 Lectin, galactoside-binding, soluble, 3 (galectin 3) /// galectin-3 internal gene 0.23 0.21
NOTCH2NL Notch homolog 2 (Drosophila) N-terminal like 0.29 0.26
MELANOMA MARKERS
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
MAGEA1 Melanoma antigen family A, 1 (directs expression of antigen MZ2-E) 2.78 2.78
CSPG4 Chondroitin sulfate proteoglycan 4 (melanoma-associated) 0.19 0.24
MIA Melanoma inhibitory activity 0.48 0.44
S100A1 S100 calcium binding protein A1 0.33 0.13
S100A13 S100 calcium binding protein A13 0.38 0.33
S100A16 S100 calcium binding protein A16 0.29 0.36
S100A2 S100 calcium binding protein A2 0.30 0.27
S100A3 S100 calcium binding protein A3 0.15 0.12
S100A4 S100 calcium binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog) 0.10 0.09
S100B S100 calcium binding protein, beta (neural) 0.13 0.10
TRANSCRIPTION FACTORS
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
FOXF2 Forkhead box F2 2.16 2.32
SOX11 SRY (sex determining region Y)-box 11 3.85 4.10
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TRANSCRIPTION FACTORS
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
SOX9 SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) 2.27 12.34
NFATC2 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 0.29 0.22
SOX2 SRY (sex determining region Y)-box 2 0.41 0.46
SOX5 SRY (sex determining region Y)-box 5 0.20 0.08
TBX2 T-box 2 0.24 0.19
APOPTOSIS
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
BID BH3 interacting domain death agonist 2.17 2.28
NGFR Nerve growth factor receptor (TNFR superfamily, member 16) 6.67 4.56
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 0.46 0.23
BCL2A1 BCL2-related protein A1 0.04 0.05
BIRC3 Baculoviral IAP repeat-containing 3 0.36 0.18
FAIM3 Fas apoptotic inhibitory molecule 0.32 0.30
FAS Fas (TNF receptor superfamily, member 6) 0.19 0.19
TNFSF7 Tumor necrosis factor (ligand) superfamily, member 7 0.33 0.35
CELL PROLIFERATION
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
CCNJ Cyclin J 2.04 2.91
CLEC11A C-type lectin domain family 11, member A 3.94 3.52
CYR61 Cysteine-rich, angiogenic inducer, 61 2.06 2.55
E2F5 E2F transcription factor 5, p130-binding 3.72 3.91
HDAC9 Histone deacetylase 9 2.51 3.35
MDK Midkine (neurite growth-promoting factor 2) 7.29 9.42
CCNA1 Cyclin A1 0.10 0.08
CDKN1A Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.21 0.37
DUSP4 Dual specificity phosphatase 4 0.39 0.32
HIPK2 Homeodomain interacting protein kinase 2 0.41 0.41
IGF1R Insulin-like growth factor 1 receptor 0.25 0.25
IGFBP2 Insulin-like growth factor binding protein 2, 36kDa 0.24 0.14
IGFBP5 Insulin-like growth factor binding protein 5 0.27 0.27
IGFBP7 Insulin-like growth factor binding protein 7 0.32 0.45
NDN Necdin homolog (mouse) 0.07 0.09
CYTOKINES
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
IL13RA2 Interleukin 13 receptor, alpha 2 0.41 0.44
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CYTOKINES
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
IL1A Interleukin 1, alpha 0.16 0.11
IL1RAP Interleukin 1 receptor accessory protein 0.17 0.14
IL24 Interleukin 24 0.06 0.07
IL6ST Interleukin 6 signal transducer (gp130, oncostatin M receptor) 0.38 0.38
METABOLISM
Gene symbol Description
PEDF/Control
Hybr. 1 Hybr. 2
PLTP phospholipid transfer protein 2.73 2.71
ACOX2 acyl-Coenzyme A oxidase 2, branched chain 0.49 0.30
ACSL1 acyl-CoA synthetase long-chain family member 1 0.34 0.39
ADPGK ADP-dependent glucokinase 0.39 0.38
B3GAT1 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) 0.35 0.29
CHST11 carbohydrate (chondroitin 4) sulfotransferase 11 0.36 0.18
IRS2 insulin receptor substrate 2 0.44 0.40
MGLL monoglyceride lipase /// monoglyceride lipase 0.24 0.44
PLA2G4A phospholipase A2, group IVA (cytosolic, calcium-dependent) 0.24 0.38
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